Biocon Gets USFDA Observations for Bengaluru API Facility

Sep 28, 2024 17:49

Biocon's Bengaluru-based API facility received four observations from the USFDA following an inspection. The company plans to address the observations within the stipulated time.

Photograph: Kind courtesy Biocon

New Delhi, Sep 28 (PTI) Biocon on Saturday said the US health regulator has issued four observations after inspecting its Bengaluru-based API (active pharmaceutical ingredient) facility.

The US Food and Drug Administration (USFDA) conducted a surveillance inspection of the API facility (Site 2), located at Bengaluru from September 23- 27, 2024, the company said in a regulatory filing.

"Four observations were cited at the end of the inspection, which the company will be addressing within the stipulated time," it added.

The company does not foresee any impact on the business, Biocon said.

Source: PTI

MORE NEWS

Lulu Group Returns to Andhra Pradesh for...

Lulu Group, a major conglomerate, is set to invest in Andhra Pradesh after a change in...

Made-in-India Goods: Goyal Calls for Increased Use

Commerce Minister Piyush Goyal urges increased use of made-in-India goods to boost...

Flipkart Sees Huge Surge in Credit Purchases...

Flipkart reports a significant increase in customer purchases using credit during its...

Amul Turnover Rises 8% to Rs 59,445 Cr in FY24

GCMMF, the operator of Amul brand, reports an 8% increase in turnover to Rs 59,445...

REC Raises USD 500 Million via Green Bond

REC Ltd has raised USD 500 million through green dollar bonds to finance renewable...

Agri Startups Training: Chouhan Calls for...

Agriculture Minister Shivraj Singh Chouhan emphasizes the importance of training for...

Rice Export Ban Lifted: Relief for Bengal...

India lifts ban on non-basmati white rice exports, bringing relief to Bengal's...

India SME Forum Launches 'Start Exporting in...

India SME Forum launches 'Start Exporting in Eight Weeks' program to help MSMEs access...

DPIIT to Decriminalise Minor Offences with Jan...

DPIIT is working on 100 rules to decriminalise minor offenses under Jan Vishwas 2.0,...

Meesho Festive Sale: 6.5 Cr Visitors, Orders...

Meesho's 'Mega Blockbuster Sale' sees a record-breaking 6.5 crore unique visitors on...

Biocon Gets USFDA Observations for Bengaluru API Facility

You May Like To Read

MORE NEWS